Acute Lymphoblastic Leukemia, in Relapse Clinical Trial
— CARTHIAE-1Official title:
A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
This is a phase l, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | December 1, 2028 |
Est. primary completion date | May 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Subjects must have relapsed or refractory ALL, lymphoma or CLL treated with at least two lines of therapy. Disease must have either progressed after the last regimen or presented failure to achieve partial or complete remission with the last regimen. Subjects with Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ALL) subjects are eligible if they progressed, had stable disease or relapsed after two lines of therapy, including tyrosine kinase inhibitors (TKIs). Subjects with DLBCL must have progressed, had SD, or recurred after initial treatment regimens that include an anthracycline and an anti-CD20 monoclonal antibody. Subjects with transformed FL, MZL, or CLL/SLL must have progressed, had SD or recurred with transformed disease after initial treatment for DLBCL. Subjects who relapse =12 months after therapy should have progressed after autologous transplant or been ineligible for autologous transplant. 2. 2. The patient's disease must be CD19 positive, either by immunohistochemistry or flow cytometry analysis on the last biopsy available. 3. Age 2 to 70 years. 4. Performance status: Adult Subjects: ECOG = 2 for patients = 16 years; Subjects < 16 years of age: lansky = 50% 5. Normal Organ and Marrow Functioning (supportive treatment is allowed according to institutional standards, i.e. filgrastim, transfusion) • Total Bilirubin = 2; AST (SGOT) = 5 times the upper limit of normal; ALT (SGTP) = 5 times the upper limit of normal; Serum creatinine = 1.5; Pulse oximetry >91% on room air; No dyspnea or mild dyspnea (= Grade 1); Forced expiratory volume in 1 s (FEV1) =50% or carbon monoxide diffusion test (DLCO) =50% of predicted level; Left ventricular ejection fraction = 45% confirmed by echocardiogram; Subjects must have the following hematologic function parameters: Neutrophils > 1000/uL; Absolute Lymphocyte Count > 100/uL; Platelets = 50,000/L Patient should not be excluded if change of the above parameters due to spinal cord disease infiltration; 6. Prior therapy wash-out - At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis, except for systemic inhibitory/stimulatory immune checkpoint therapy, which requires 5 half-lives, Blinatumomab with 4 months prior CAR-T infusion. 7. For women of reproductive potential: use a highly effective contraceptive for at least 1 month prior to screening and agree to use a method during study participation and for an additional 4 months after CAR T-cell administration has ended. 8. Subjects must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Autologous transplant within 6 weeks of planned CAR-T cell infusion; 2. History of allogeneic stem cell transplant 4 months prior CAR T cell infusion. 3. Use of immunosuppression therapy; • Patients must have completed immunosuppression therapy; Systemic corticosteroid therapy must be stopped more than 72 hours after infusion; Systemic drugs for graft-versus-host disease should be withheld at least 4 weeks prior to infusion; 4. Presence of graft-versus-host disease Grade = 2; 5. Receiving CAR T cell treatment outside of this protocol; 6. Active central nervous system or meningeal involvement by tumor. Subjects with untreated brain metastases/CNS disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with a history of CNS or meningeal involvement must be in a documented remission by CSF evaluation and contrast-enhanced MRI imaging for at least 90 days prior to registration. 7. History of active malignancy other than non-melanoma skin cancer, carcinoma in situ (e.g. cervix, bladder, breast). 8. HIV infection; HTLV 9. Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities or psychiatric illness/social situations that would limit compliance with study requirements. 10. Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. 11. Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy 12. Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.) 13. Serious and/or potentially fatal medical conditions 14. Patients with history of clinically relevant CNS pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease. 15. History of autoimmune disease (i.e. rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months. 16. Hypersensitivity against any drug or its ingredients/impurities that is scheduled or likely to be given during trial participation, e.g. as part of the mandatory lymphodepletion protocol, pre-medication for infusion, rescue medication/salvage therapies for treatment related toxicities; |
Country | Name | City | State |
---|---|---|---|
Brazil | Hospital Israelita Albert Einstein | São Paulo |
Lead Sponsor | Collaborator |
---|---|
Hospital Israelita Albert Einstein | Miltenyi Biotec, Inc. |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determination of the recommended dose of CAR-T cells for a future phase II study | The RP2D will be the maximum tolerated dose (MTD) or the highest dose studied if an MTD is not obtained. | Until day 28 after CAR-T cells infusion | |
Secondary | Response to treatment for each timepoint. | ORR in ALL (Rate of CR/CRh) | day 28 | |
Secondary | Response to treatment for each timepoint | ORR in NHL/CLL (Rate of CR/CRh) | day 28, patients not in CR on day 28: month 3 | |
Secondary | Assess overall survival (OS), progression-free survival (PFS). | Overall survival (OS) and progression-free survival (PFS) will be assessed by dose cohort and in the first two groups at the MTD (or at the highest dose studied). | at 1 year after CAR-T infusion | |
Secondary | Phenotype and persistence of CAR-T | Blood samples for determination of persistence/phenotyping of infused CAR-T cells will be analysed. | days 2, 7, 10, 14, 28, weeks 8, 12, months 6, 12, 24, 36, 48, 60 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05066958 -
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
|
Phase 1/Phase 2 | |
Completed |
NCT04224571 -
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children
|
Phase 2 | |
Recruiting |
NCT04888442 -
Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL
|
Phase 1 | |
Recruiting |
NCT05809284 -
Determining the Mechanisms of Loss of CAR T Cell Persistence
|
||
Recruiting |
NCT04049383 -
CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL
|
Phase 1 | |
Not yet recruiting |
NCT05745714 -
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05740449 -
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06213636 -
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
|
Phase 1/Phase 2 | |
Recruiting |
NCT04603872 -
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
|
Early Phase 1 | |
Recruiting |
NCT04475731 -
Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse
|
Phase 2 | |
Recruiting |
NCT06445803 -
CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
|
Phase 1 | |
Recruiting |
NCT03957915 -
Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia
|
Early Phase 1 | |
Terminated |
NCT03705507 -
International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04340167 -
Study of Anti-CD22 CAR-T Cells Treating Leukemia Children
|
Phase 2 | |
Recruiting |
NCT04605666 -
CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT04325841 -
Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children
|
Phase 2 | |
Active, not recruiting |
NCT04340154 -
Study of Sequential CAR-T Cell Treating Leukemia Children
|
Phase 2 | |
Recruiting |
NCT05292664 -
Venetoclax Basket Trial for High Risk Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT06316427 -
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05310591 -
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
|
Phase 1/Phase 2 |